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ABSTRACT 32 
Background:  The interaction of nutrients with the small intestine modulates 33 
gastropyloroduodenal motility, stimulates the release of gut hormones, and suppresses appetite 34 
and energy intake. 35 
Objective:  To evaluate in healthy, lean males, which, if any, of these parameters are 36 
independent determinants of acute energy intake. 37 
Design:  Data from eight published studies, involving a total of 67 healthy, lean males, in 38 
which antropyloroduodenal pressures, gastrointestinal hormones and perceptions were 39 
measured during intraduodenal nutrient, or intravenous hormone, infusions, were pooled.  In all 40 
studies energy intake at a buffet lunch was quantified immediately after the infusions.  To select 41 
specific motor, hormone or perception variables for inclusion in a multi-variable mixed-effects 42 
model for determination of independent predictors of energy intake, all variables were assessed 43 
for collinearity and, using bivariate analyses adjusted for repeated measures, within-subject 44 
correlations between energy intake and these variables were determined. 45 
Results: While correlations were found between energy intake with antropyloroduodenal 46 
pressures, plasma hormone concentrations and gastrointestinal perceptions, only the peak 47 
number of isolated pyloric pressure waves, peak plasma cholecystokinin and AUC of nausea 48 
were identified as independent predictors of energy intake (all P<0.05), so that increases of 1 49 
pressure wave, 1 pmol/L and 1 mm.min, respectively, were associated with reductions in 50 
energy intake by ~36 kJ, ~88 kJ and 0.4 kJ, respectively. 51 
Conclusions:  We have identified specific changes in gastrointestinal motor and hormone 52 
function, i.e. stimulation of pyloric pressures and plasma CCK, and nausea, that are associated 53 
with the acute suppression of energy intake.   54 
 55 
Key words: Gastrointestinal motility; glucagon-like peptide-1; peptide YY; intraduodenal 56 
nutrient infusion; appetite perceptions57 
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INTRODUCTION 58 
In Western countries, the prevalence of obesity has more than doubled over the past three 59 
decades (1).  Hence, there is an urgent need for effective prevention and treatment strategies.  60 
Numerous dietary and pharmacological treatments for obesity have been developed, however, 61 
most have limited efficacy and, in the case of drugs, adverse effects occur frequently (2).  The 62 
available therapies have largely ignored the pivotal role of the gastrointestinal (GI) tract in the 63 
regulation of appetite and energy intake in humans (3-9).   64 
 65 
The modulation of energy intake by the GI tract is likely to involve both motor and hormonal 66 
mechanisms.  While distension of both the proximal and distal stomach increases fullness (10, 67 
11) and suppresses energy intake (4, 12), the antrum may play the dominant role (4, 10).  The 68 
presence of nutrients in the small intestine slows gastric emptying potently, by decreasing antral 69 
motility and stimulating phasic and tonic pyloric pressure waves, and stimulates the release of 70 
GI hormones, including cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-71 
1 (GLP-1) (13, 14), which may mediate the concomitant inhibition of appetite and subsequent 72 
energy intake.  For example, studies using the CCK-1 receptor antagonist, loxiglumide, have 73 
established that endogenous CCK inhibits energy intake (6, 15, 16).  Exogenous PYY(3-36) and 74 
GLP-1 have also been reported to decrease energy intake in some (5, 17), but not all (18-20), 75 
studies.  We recently reported an inverse relationship between the suppression of energy intake 76 
and stimulation of pyloric pressures in response to intravenous CCK-8 infusion in healthy 77 
males (7), providing evidence of a link between specific changes in GI motor function and the 78 
suppression of energy intake in humans.  Since modulations in antropyloroduodenal motility 79 
underlie the slowing of gastric emptying (21), with pyloric pressures playing the dominant role 80 
(22), this finding provides a rationale to account for the relationship between the slowing of 81 
gastric emptying and the suppression of energy intake reported previously (23).  Changes in 82 
motility and hormone secretion occur concurrently with changes in appetite, and it is, 83 
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accordingly, not surprising that there is little information as to which, if any, of these factors are 84 
independent determinants of energy intake.  For example, while CCK does have a role, this may 85 
potentially be mediated indirectly by its effect on motility (7, 19).   86 
 87 
During the last few years, we have performed a series of studies in our laboratory in healthy 88 
males, relating to GI motor and hormonal function and appetite and energy intake in response to 89 
small intestinal nutrient (8, 24-29) or intravenous hormone (7, 19, 30) administration, 90 
accumulating a substantial body of data.  A focus of this work has been on pyloric motility, 91 
given that the pylorus is of pivotal importance to the regulation of gastric emptying (22), but 92 
has hitherto received inappropriately little attention.  Individually, such studies are often limited 93 
by small sample sizes, so that it is only possible to perform simple correlation or regression 94 
analyses between energy intake and physiological parameters, uncontrolled for other concurrent 95 
physiological changes.  Pooling data from these studies has enabled us to generate a uniquely 96 
large set of data to examine the simultaneous relationships amongst multiple parameters and, 97 
thus, to determine independent predictors of acute energy intake.98 




A total of 67 subjects, with a mean age of 26 ± 1 years and normal body weight for their height 101 
(BMI 23.3 ± 0.3 kg/m2), participated in the studies that were included in this analysis (7, 8, 19, 102 
24-30).  Of the 67 subjects, 6 subjects participated in 2, 4 subjects in 3, and 2 subjects in 5 103 
studies.  Information relating to the subjects in each study is provided in Table 1.  All subjects 104 
were unrestrained eaters, as determined by a score of <12 on the eating restraint component of 105 
the three-factor eating questionnaire (31) and were questioned prior to the study to exclude 106 
significant GI symptoms or disease, current use of medication known to affect GI function or 107 
appetite, cigarette smoking, or intake of >20 g alcohol/day.  The Royal Adelaide Hospital 108 
Research Ethics Committee approved the study protocols, and the studies were initiated 109 
between May 2003 - July 2008.  All subjects provided informed, written, consent prior to their 110 
inclusion.  111 
 112 
Study design 113 
Data from eight published studies (7, 8, 19, 24-30), representing all studies conducted in our 114 
laboratory using identical methodologies and techniques and evaluating the same outcome 115 
measures, were pooled for analysis.  The data were then analyzed employing the same 116 
statistical tests that would be appropriate for a full meta-analysis, although it is inappropriate to 117 
refer to the current study as such, given that the included studies were not identified through a 118 
systematic review (32). 119 
 120 
Study protocols 121 
Each study evaluated the effects of either intraduodenal nutrient (8, 24-29) or intravenous 122 
hormone (7, 19, 30) infusions on antropyloroduodenal motility, GI hormone release, appetite 123 
and energy intake.  Intraduodenal or intravenous infusions, rather than oral ingestion, were used 124 
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in these studies to bypass ‘orosensory’ and ‘gastric’ influences on gut function and appetite.  125 
Energy intake was assessed at the end of the duodenal nutrient infusion period, or during the 126 
final 30 min of the intravenous hormone infusion, using a cold buffet-style meal.  The 127 
treatments and infusion periods in each of the studies varied, and the protocol details are 128 
provided in Table 1. 129 
 130 
In all studies, subjects arrived in the laboratory after an over-night fast.  A 16-channel catheter 131 
(Dentsleeve International Ltd, Ontario, Canada), for the assessment of pressures in the 132 
antropyloroduodenal region, was inserted through an anesthetized nostril into the stomach, and 133 
allowed to pass into the duodenum by peristalsis (22).  Six side-holes (channels 1 - 6) were 134 
positioned in the antrum, a 4.5 cm sleeve sensor (channel 7), with two channels present on the 135 
back of the sleeve (channels 8 and 9), was positioned across the pylorus, and seven side-holes 136 
(channels 10 - 16) were positioned in the duodenum.  Side-holes were spaced at 1.5 cm 137 
intervals.  An additional channel, positioned 11.75 cm distal to the pylorus, was used for 138 
intraduodenal infusion of nutrients or saline control (8, 24-29).  Both the most distal antral 139 
(channel 6, ~ - 40mV), and the most proximal duodenal (channel 10, ~ 0mV), channels were 140 
perfused with degassed 0.9% saline so that the position of the catheter could be monitored 141 
continuously through measurement of the transmucosal potential difference (22).  For this, an 142 
intravenous cannula was placed subcutaneously in the left forearm and filled with sterile saline 143 
as a reference electrode (22).  All other channels were perfused with degassed, distilled water at 144 
0.15 ml/min.  For intravenous infusions of saline, CCK-8 or GLP-1, an intravenous cannula was 145 
placed in the right arm (7, 19, 30).  A second intravenous cannula was inserted into a left 146 
forearm vein for blood sampling, and blood samples were obtained at regular intervals during 147 
studies.  Gastrointestinal perceptions were assessed at regular intervals using a validated visual 148 
analogue scale questionnaire (VAS) (33).  At the end of each infusion, subjects were extubated 149 
and offered a cold buffet-style meal to consume freely for up to 30 min, until comfortably full.  150 
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The meal consisted of white and whole-meal breads, cold meats, cheese, lettuce, tomato, 151 
cucumber, mayonnaise, butter, apple, banana, yoghurt, chocolate custard, fruit salad, iced 152 
coffee, orange juice and water, and the quantities of food offered were in excess of what the 153 
subjects were expected to eat (19).   154 
 155 
Data analysis 156 
The parameters assessed in each study are detailed in Table 2.   157 
 158 
Manometric pressures were digitized and recorded on a computer-based system, running 159 
commercially available software (HAD, A/Prof GS Hebbard, Royal Melbourne Hospital, 160 
Australia), and stored for subsequent analysis.  APD pressures were analyzed for (i) number 161 
and amplitude of antral and duodenal pressure waves (PWs), and (ii) basal pyloric pressure and 162 
number and amplitude of isolated pyloric pressure waves (IPPWs), using previously described 163 
criteria (34, 35).  Antral and duodenal PWs were expressed as total numbers and mean 164 
amplitudes (mmHg).  IPPWs, defined as pyloric pressure waves that occur in the absence of 165 
pressure waves on adjacent antral and duodenal channels, were characterized by the peak 166 
number during the infusion, time to peak number (min), number of IPPWs pre-meal (i.e. 167 
immediately before the buffet meal), total number and area under the curve (AUC; calculated 168 
using the trapezoidal rule, as a measure over the entire infusion period) (min), and AUC of the 169 
amplitude of IPPWs (mmHg.min).  Basal pyloric pressure, or tone, was expressed as peak 170 
pressure (mmHg), time to peak pressure (min) and AUC (mmHg.min).   171 
 172 
For subsequent analysis of CCK, PYY and GLP-1, venous blood samples were collected in ice-173 
chilled EDTA-treated tubes containing 400 kIU aprotinin (Trasylol; Bayer Australia Ltd, 174 
Pymble, Australia) per ml blood.  Plasma was obtained by centrifugation of blood samples at 175 
3200 rpm for 15 min at 4oC, and plasma was frozen at -70oC for subsequent analysis of CCK 176 
Seimon et al.  9 
 
(7, 8, 19, 25-29), GLP-1 (8, 19, 26, 28) and PYY (7, 24, 25, 27, 29, 30) by radioimmunoassays.  177 
Plasma CCK, PYY and GLP-1 concentrations were expressed as AUC (pmol/L.min) and 178 
plasma concentrations pre-meal (pmol/L) and, for plasma CCK concentrations, peak 179 
concentration (pmol/L) and time to peak concentrations (min) were calculated.  The latter were 180 
not calculated for plasma PYY and GLP-1, as these did not generally reach a peak, but 181 
continued to rise, throughout the infusion periods.   182 
 183 
Appetite perceptions were rated using a validated VAS questionnaire (33).  Nausea and bloating 184 
were also assessed.  Each VAS consisted of a 100 mm horizontal line, where 0 represented 185 
‘sensation not felt at all’ and 100 represented ‘sensation felt the greatest’.  Subjects placed a 186 
vertical mark along the line to indicate the strength of the sensation felt at that particular time 187 
point.  All data were expressed as AUC (mm.min).  Energy intake (kJ) was quantified by 188 
weighing the buffet meal before and after consumption and using the software programme 189 
Foodworks 3.01 (Xyris Software, Highgate Hill, QLD, Australia) (19). 190 
 191 
Statistical analysis  192 
Data are reported as means (± SEM).  To assess the strength of the bivariate relationships 193 
between each motility, hormone, and perception variable with energy intake, within-subject 194 
correlations adjusted for repeated measures were performed (36).  The independent effects of 195 
each motility, hormone and perception variable on energy intake were assessed by entering the 196 
variables simultaneously into a multi-variable maximum likelihood linear mixed-effect model, 197 
adjusted for repeated visits per subject and the clustering of subjects within studies (37).  This is 198 
equivalent to the ‘one-step’ analysis approach in a meta-analysis of individual participant data 199 
(38).  All variables were included in the multi-variable model, except when collinearity 200 
(defined as r > 0.7) was present.  In this case, of the related variables from within the same 201 
underlying motility, hormone or perception parameter, only one was selected for inclusion into 202 
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the model, to ensure the robustness of the regression estimates.  This variable was selected 203 
based on consistency across studies and the strength of bivariate associations with energy 204 
intake.  As not all parameters were measured in all studies (see Table 1), the multi-variable 205 
analysis was conducted as three separate models.  Model 1 included parameters that were 206 
measured in all eight studies.  Model 2 included all parameters in Model 1 plus PYY (6 207 
studies), while Model 3 included all parameters from Model 1 plus GLP-1 (4 studies).  To test 208 
for potential selection effects, Model 1 was re-run on the 4 studies used in Model 3, to ensure 209 
that a particular variable was not identified as independent depending on which studies were 210 
included in the Model and to ensure that no variables were under-represented.  Analyses were 211 
conducted using SPSS 17 software (SPSS Inc, 2008, Chicago, USA).  Significance was 212 
determined at P < 0.05.213 
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RESULTS 214 
Bivariate correlation analyses 215 
Within-subject correlations between energy intake and each of the measured parameters are 216 
presented in Table 3. 217 
 218 
Collinearity was present amongst a number of variables, thus, only one could be entered into 219 
the multi-variate model to guarantee robust estimation of the regression effects.  Within the 220 
variables characterizing IPPWs, peak number, total number and AUC of the number were 221 
strongly associated with each other (all r > 0.74).  Of these, peak number was selected for 222 
inclusion in the multi-variable model, as it exhibited the strongest correlation with energy 223 
intake.  Of the CCK parameters, peak concentration was strongly correlated with both AUC and 224 
pre-meal concentrations (both r > 0.85), and thus peak concentration was selected, as, of those 225 
three variables, it best characterized the CCK response.  For PYY and GLP-1, pre-meal levels 226 
were strongly associated with the corresponding AUCs (both r > 0.84), thus, AUCs were 227 
included in the multi-variable model, as they best characterized these hormone profiles.  Of the 228 
appetite-related scores, hunger, desire-to-eat and prospective consumption were strongly 229 
correlated with each other (all r > 0.82), thus, prospective consumption was included in the 230 
model, as it showed the strongest correlation with energy intake.  All other variables were 231 
entered automatically into the multi-variable model, due to the absence of any multi-232 
collinearity. 233 
 234 
Multi-variable mixed-effects models 235 
In all three models, the peak number of IPPWs, peak plasma CCK concentration and AUC for 236 
nausea were consistently identified as independent predictors of energy intake (all P < 0.05, 237 
Table 4), so that an increase in each of these variables by 1 pressure wave, 1 pmol/L and 1 238 
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mm.min, while controlling for all other parameters, was associated with a reduction in energy 239 
intake by ~36 kJ, ~88 kJ and 0.4 kJ, respectively.   240 
 241 
In addition, models 1 and 2 indicated that the number of IPPWs pre-meal was independently 242 
associated with energy intake (P < 0.05).  However, in contrast to the peak number of IPPWs, 243 
an increase in the number of IPPWs pre-meal by 1 pressure wave was associated with an 244 
increase in energy intake by ~19 kJ.   245 
 246 
Model 2 further identified the time to peak number of IPPWs and peak basal pyloric pressure, 247 
but not plasma PYY concentration, as significantly associated with energy intake (all P < 0.05, 248 
Table 4).  An increase in the time to peak number of IPPWs by 1 min, while controlling for all 249 
other parameters, was associated with a reduction in energy intake by ~10 kJ.  In contrast, an 250 
increase in peak basal pyloric pressure by 1 mmHg increased energy intake by ~68 kJ.   251 
 252 
Finally, model 3 indicated that the plasma GLP-1 concentration was not an independent 253 
predictor of energy intake. 254 
 255 
The robustness of the above results was confirmed by re-running Model 1 (complete set of 256 
variables) on the subset of 4 studies that were used in Model 3 (data not shown).  Despite the 257 
reduction in the number of studies included in the model from 8 to 4, peak number of pyloric 258 
pressures, plasma CCK concentrations and nausea were identified as independent determinants 259 
of energy intake, confirming the above results. 260 
261 
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DISCUSSION 262 
Our study provides persuasive evidence of a direct relationship between energy intake with 263 
specific changes in gastric motility and gut hormones.  When controlling for all other variables, 264 
the peak number of isolated pyloric pressure waves, peak plasma CCK concentrations and AUC 265 
of nausea were consistently, i.e. in all three statistical models, identified as independent 266 
predictors of acute energy intake in healthy males.  267 
 268 
It has long been assumed that acute changes in GI function in response to nutrient ingestion, 269 
which serve to optimize digestion and absorption of nutrients, also play a key role in the 270 
regulation of energy intake.  For example, in dogs electrical stimulation of the pylorus, which 271 
increases both tonic and phasic pyloric pressures, is associated with suppression of energy 272 
intake (39), in line with our recent finding of an inverse relationship between the stimulation of 273 
pyloric pressures and subsequent energy intake (7).  While the latter did not establish a causal 274 
association, the outcome of the extensive statistical analyses performed in the current study 275 
strongly supports this concept.  Thus, the magnitude of stimulation of IPPWs (specifically the 276 
peak number) independently determines the degree of suppression of acute energy intake.  277 
Since pyloric stimulation is a major determinant of the slowing of gastric emptying (22), it 278 
could be argued, that prolongation of gastric filling underlies the ‘pyloric’ effects.  However, as 279 
in all our studies the stomach was empty, it is clear that pyloric pressures may have a 280 
suppressant effect on energy intake, even in the absence of gastric filling.  The number of 281 
IPPWs pre-meal and peak basal pyloric pressure indicated effects on energy intake in a counter-282 
intuitive positive direction, and the reason(s) underlying this are unclear.  It can be difficult to 283 
predict the direction of individual effects when controlling for other, inter-related, parameters 284 
and, as these parameters were not identified consistently in all three models, this may well 285 
represent a statistical anomaly.   286 
 287 
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There has been, and continues to be, substantial interest in the role of gut peptides in the 288 
regulation of energy intake, with the view to develop novel anti-obesity strategies.  CCK is 289 
probably the best-studied of all gut peptides (7, 12, 40).  Together with these previous data, our 290 
findings that peak plasma CCK concentration is an independent determinant of acute energy 291 
intake underlines the importance of CCK in the regulation of acute energy intake.  Given that it 292 
is well established that CCK, when given intravenously, has a marked stimulatory effect on 293 
pyloric pressures (7, 41), by acting on CCK-1 receptors located on the pylorus (42), it could be 294 
argued that the effect of CCK on energy intake depends on its action on the pylorus.  However, 295 
our statistical approach, which, when assessing one parameter, controls for all other variables, 296 
shows clearly that the two stimuli act independently.  That the pylorus plays an independent 297 
role is supported by a recent study in dogs, in which electrical pyloric stimulation, in the 298 
absence of CCK, was associated with suppression of food intake (39).  This said, it is important 299 
to recognize that while our statistical analysis indicated that these factors acted independently 300 
of each other, the information from both signals (as well as others) is transmitted to the brain 301 
and integrated within the central nervous system to result in the overall outcome, ie the 302 
magnitude of energy intake suppression. 303 
 304 
The peak stimulation of both IPPWs and plasma CCK occurred 15 - 30 min after 305 
commencement of the intraduodenal nutrient or intravenous hormone infusions (8, 19, 24-30), 306 
and these responses had diminished by the time energy intake was assessed, consistent with the 307 
concept that the information was encoded in the brain and translated into a suppression in 308 
energy intake even after a temporal delay, yet still inversely proportionate to the maximum 309 
pyloric and CCK stimulation that occurred 60 - 90 min earlier.  This relationship clearly 310 
warrants further investigation in prospective studies, but the finding offers initial insights as to 311 
how information on the extent of peripheral nutrient or hormonal stimulation may be conveyed 312 
to, and then used by, the brain to determine subsequent energy intake. 313 
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 314 
The effects of PYY(3-36), the active metabolite of PYY, on energy intake have been the subject 315 
of much debate, with a number of studies reporting profound suppressant effects of ~30 % (5, 316 
43), in lean and obese humans, while extensive studies in rodents found no such effects (18).  A 317 
study by Degen and colleagues provided a conceivable explanation for this major discrepancy 318 
by demonstrating that the suppressant effect of PYY(3-36) on energy intake in humans is only 319 
apparent at pharmacological doses and coincides with the induction of nausea (44).  Thus, our 320 
finding that PYY is not an independent predictor of energy intake is not surprising, particularly 321 
since the vast majority of individuals did not experience overt nausea or other adverse effects 322 
during any of the treatment conditions.  The fact that CCK stimulates the release of PYY (30), 323 
an action mediated by CCK-1 receptors (45), may, at least in part, explain why PYY was not 324 
identified as an independent predictor of energy intake.  Data relating to the role of GLP-1 in 325 
the regulation of energy intake are also inconsistent.  While many studies have demonstrated 326 
that intravenous infusion of GLP-1 suppresses energy intake (17, 46, 47), other studies found 327 
no effect (19, 20, 48, 49).  We did not identify plasma GLP-1 concentration as an independent 328 
predictor of energy intake.  Other gut peptides, including ghrelin and pancreatic polypeptide, 329 
have also been reported to modify energy intake in humans (50, 51).  We were unable to 330 
investigate the potential contribution of these peptides. 331 
 332 
Our findings of correlations between appetite perceptions and subsequent energy intake confirm 333 
data from a previous study in young and older subjects (33) and are not surprising.  In contrast, 334 
our analysis indicated that appetite perceptions are not determinants of energy intake.  Perhaps 335 
this can be explained by our study design - intraduodenal infusion of nutrients or intravenous 336 
administration of gut peptides may not elicit the same feelings of fullness and satisfaction 337 
compared with oral meal ingestion, as both orosensory and gastric mechanisms are bypassed.  338 
Alternatively, it may suggest that the degree of hunger preceding a meal is not a good predictor 339 
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of the amount consumed at that meal.  Interestingly, nausea was identified as an independent 340 
predictor of energy intake.  We cannot entirely exclude the possibility that nausea occurred as a 341 
result of the direct intraduodenal nutrient, or intravenous hormone administrations utilized in all 342 
our studies, but it is important to emphasize that, on average, nausea scores did not increase by 343 
more than ~10 %.  Hence, the statistical outcome of nausea as an independent predictor of 344 
energy intake is based on very modest changes, suggesting that energy intake may, at least in 345 
part, be regulated by subtle feelings of nausea, only perceived subconsciously by the subjects.  346 
That said, our analysis also indicated that the contribution of nausea to the suppression of 347 
energy intake is very small, particularly when compared with the effect of pyloric stimulation 348 
and CCK.  More research is required to determine how nausea may be part of the spectrum of 349 
appetite perception.   350 
 351 
Some limitations of the study need to be recognized.  All studies were performed in healthy, 352 
lean males, accordingly, we cannot draw any firm conclusions with regards to outcomes in 353 
females, with increasing body weight or age.  Only sub-sets of studies evaluated plasma PYY 354 
and GLP-1 concentrations, which may have influenced the statistical outcomes, however, the 355 
standard errors for these parameters remained within reasonable limits, indicating sufficient 356 
statistical power, and the main outcomes were confirmed when model 1 was repeated including 357 
only the four studies included in model 3.  While the studies were performed over a number of 358 
years, the techniques, equipment and calibration methods used were identical and the within-359 
subject reproducibility of our techniques is very good (52).  Moreover, inter-individual 360 
variations in responses were taken into account by employing a multi-variable mixed effects 361 
model appropriate for this type of data analysis.   362 
 363 
In conclusion, our findings provide strong evidence that pyloric pressures, plasma CCK and 364 
nausea are independent predictors of acute energy intake in healthy males.  Evaluation of these 365 
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parameters as determinants of energy intake, and their potential as screening tools for the 366 
appetite-suppressant potency of novel, gut-focused therapeutic agents, in prospective studies 367 
would be of interest.  Strategies modulating these GI functions to regulate energy intake have 368 
the potential to lead to novel approaches to the prevention and management of obesity.  369 
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Table 1:  Subject and protocol details for each study included in the data analyses. 520 








   1    Feltrin (2004) (8) 
        Feltrin (2006) (24) 
8 
7* 
24 ± 4 22.0 ± 1.6 Intraduodenal saline (control); dodecanoic acid (C12) or 
decanoic acid (C10) at 0.375 kcal/min for 90 min. Buffet 
meal at 90 min. 
   2  Little (2005) (28) 13 23 ± 2 23.6 ± 0.5 Intraduodenal saline; C12 at 0.1, 0.2 or 0.4 kcal/min for 
90 min. Buffet meal at 90 min. 
   3   Brennan (2005) (19) 
        Brennan (2007) (30) 
9 22 ± 1 23.0 ± 0.5 Intravenous saline; CCK-8 (1.8 pmol/kg/min), GLP-1 
(0.9 pmol/kg/min) or CCK-8+GLP-1 for 150 min. Buffet 
meal at 120 min. 
   4    Pilichiewicz (2007) (26) 10 32 ± 4 25.1 ± 0.4 Intraduodenal saline; 25% glucose at 1, 2 or 4 kcal/min 
for 120 min. Buffet meal at 120 min. 
   5   Pilichiewicz (2007) (27) 16 31 ± 3 23.8 ± 0.5 Intraduodenal saline; lipid at 0.25, 1.5 or 4 kcal/min for 
50 min. Buffet meal at 50 min. 
   6   Brennan (2008) (7) 10 26 ± 2 23.0 ± 0.5 Intravenous saline; CCK-8 at 0.3, 0.6 or 1.8 pmol/kg/min 
for 120 min. Buffet meal at 90 min. 
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   7   Feltrin (2008) (25) 13 26 ± 2 22.9 ± 0.6 Intraduodenal saline; C12 or oleic acid (C18:1) at 0.4 
kcal/min for 60 min. Buffet meal at 60 min. 
   8    Seimon (2009) (29) 10 25 ± 3 22.8 ± 0.4 Intraduodenal saline; fat emulsions with droplet sizes of 
0.26 µm, 30 µm or 170 µm at 2.8 kcal/min for 120 min. 
Buffet meal at 120 min. 
    Part of the hormone data in studies 1 and 3 were analyzed and published separately, resulting in 2 publications for these studies.  521 
    * In Study 1, sufficient plasma for the additional hormone analyses was available from only 7 of the 8 subjects.  522 
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Table 2: Parameters measured in each study 523 
CCK, cholecystokinin, PYY, peptide YY, GLP-1, glucagon-like peptide-1, X, parameter measured. 524 




















































































































































   1     Feltrin (2004) (8) 





X X X  X X X X X X X 
   X        
   2  Little (2005) (28) X X X X X  X X X X X X X 
   3    Brennan (2005) (19) 
         Brennan (2007) (30) 
X X X X X  X X X X X X X 
     X        
   4   Pilichiewicz (2007) (26) X X X X X  X X X X X X X 
   5   Pilichiewicz (2007) (27) X X X X X X  X X X X X X 
   6    Brennan (2008) (7) X X X X X X  X X X X X X 
   7     Feltrin (2008) (25) X X X X X X  X X X X X X 
   8  Seimon (2009) (29) X X X X X X  X X X X X X 
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Table 3: Within-subject correlations between energy intake and gastrointestinal motor, 525 
hormone and perception variables 526 
Parameter n* mean SD r P 
Antral pressure waves 




79.7 0.12 0.068 
     Amplitude (mmHg) 88 31.0 26.8 0.23 <0.001 
Isolated pyloric pressure waves 




10.3 -0.06 0.366 
     Peak number (/15 min) 84 20.7 12.9 -0.30 <0.001 
     Time to peak number (min) 84 25.8 20.0 -0.10 0.166 
     Total number 88 43.6 60.6 -0.12 0.052 
     AUC of number (min) 84 793 833 -0.25 <0.001 
     AUC of amplitude (mmHg.min) 84 2296 1622 -0.16 0.015 
Basal pyloric pressures 




5.2 -0.09 0.197 
     Time to peak pressures (min) 85 30.2 24.7 0.20 0.005 
     AUC (mmHg.min) 86 86 236 -0.23 <0.001 
Duodenal pressure waves 




396 0.29 <0.001 
     Amplitude (mmHg) 88 27.0 7.9 0.14 0.029 
Plasma CCK 




6.5 -0.42 <0.001 
     Peak concentration (pmol/L) 82 8.5 8.1 -0.33 <0.001 
     Time to peak (min) 82 29.8 28.3 0.02 0.784 
     AUC (pmol/L.min) 76 647 8000 -0.38 <0.001 
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Plasma PYY  




136.4 -0.23 0.005 
     AUC (pmol/L.min) 59 6933 10458 -0.22 0.006 
Plasma GLP-1  




17.3 -0.24 0.012 
     AUC (pmol/L.min) 38 1936 1424 -0.20 0.041 
Gastrointestinal perceptions      
     AUC Hunger (mm.min) 84 -853 1838 0.21 0.001 
     AUC Desire-to-eat (mm.min) 84 1044 1910 0.24 <0.001 
     AUC Prospective consumption   
(mm.min) 
84 1065 1777 0.31 <0.001 
     AUC Fullness (mm.min) 84 1745 1838 -0.12 0.080 
     AUC Nausea (mm.min) 84 297 968 -0.38 <0.001 
     AUC Bloating (mm.min) 84 838 1447 -0.28 <0.001 
AUC, area under the curve; SD, standard deviation; r, correlation coefficient; P, significance 527 
level.  528 
* Variations in the number of subjects (n) for the various parameters are due to missing data.529 
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Table 4: Results of mixed-effects multivariable models for determination of independent predictors of energy intake 530 
531 
 Model 1 Model 2                                 Model 3 
Parameter Estimate SE P Estimate SE P Estimate SE P 
Antral pressure waves 
     Number, total -2.40 1.4 0.092 -2.07 1.6 0.195 3.10 4.0 0.442 
     Amplitude, mean (mmHg) 3.75 4.0 0.354 6.10 5.5 0.268 1.19 6.2 0.850 
Isolated pyloric pressure waves 
     Number pre-meal  20.09 8.5 0.019 17.70 8.4 0.037 19.80 21.7 0.367 
     Peak number -36.85 7.4 <0.001 -39.36 8.5 <0.001 -32.32 13.9 0.025 
     Time to peak number (min) -3.29 3.4 0.341 -10.30 3.9 0.009 -4.27 5.4 0.436 
     AUC amplitude (mmHg.min) -0.03 0.1 0.619 -0.08 0.1 0.262 0.04 0.1 0.669 
Basal pyloric pressures 
     Peak pressure (mmHg) 27.47 21.6 0.206 67.91 22.4 0.003 31.63 32.5 0.334 
     Time to peak pressure (min) -2.74 3.3 0.403 -2.00 3.7 0.588 -2.55 6.2 0.682 
     AUC (mmHg.min) 0.11 0.4 0.799 -0.41 0.5 0.395 0.19 0.6 0.763 
Duodenal pressure waves 
     Number, total  0.40 0.3 0.146 0.12 0.4 0.785 0.28 0.4 0.506 
     Amplitude, mean (mmHg) -5.17 8.5 0.555 -19.52 10.3 0.062 16.62 14.9 0.269 
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AUC, area under the curve; SE, standard error of the mean; P, significance level 532 
 533 
Plasma CCK 
     Peak concentration (pmol/L)           -70.39 16 <0.001 -78.09 15.6 <0.001 -115.5 31.3 0.001 
     Time to peak conc (min) 1.55 2.6 0.551 1.37 3.1 0.657 1.73 3.9 0.656 
Plasma PYY          
     AUC (pmol/L.min) - - - 0.01 0.0 0.317 - - - 
Plasma GLP-1          
     AUC (pmol/L.min) - - - - - - 0.03 0.1 0.744 
Gastrointestinal perceptions 
     AUC Prospective consumption 
     (mm.min) 0.04 0.1 0.548 0.06 0.1 0.480 -0.01 0.1 0.918 
     AUC Fullness (mm.min) 0.04 0.1 0.516 0.12 0.1 0.151 -0.01 0.1 0.931 
     AUC Nausea (mm.min) -0.38 0.1 <0.001 -0.39 0.1 <0.001 -0.45 0.1 <0.001 
     AUC Bloating (mm.min) -0.05 0.1 0.388 -0.05 0.1 0.472 -0.13 0.1 0.179 
